Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19

• Status: Recruiting
• Trial end date: 2020-12-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group. The study will be conducted in four medical centers. From each center, 56 definitive Corona patients will be selected, who will be randomly divided into two groups of 28, for a total of 224 patients will enter the study. In the intervention group, in addition to receiving the test spray, Patients will also receive standard treatment

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baqiyatallah Medical Sciences University

Criteria

Inclusion Criteria:

• Conscious consent to participate in the study

• Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR.

• Strong clinical suspicion of covid 19 with positive findings in CT Scan

• Shortness of breath

Exclusion Criteria:

• Patients with HIV

• Patients with cancer undergoing chemotherapy

• Patients receiving Immune Mediators

• Patients need hospitalization in the intensive care unit

• Patients with uncontrolled heart, kidney or liver failure

• Pregnant or lactating women

• Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)